Nature Reviews Drug Discovery

Can multispecific biologics break the efficacy ceiling?

Asher Mullard Jul 01, 2026 pp. 497-500 10.1038/d41573-026-00106-5

Novel drug targets in 2025

Sorin Avram, Liliana Halip, Ramona Curpan et al. Jul 01, 2026 pp. 503-503 10.1038/d41573-026-00102-9

The unglamourous AI wins that are quietly transforming drug discovery and development

Asher Mullard Jul 01, 2026 pp. 507-508 10.1038/d41573-026-00099-1

Upcoming FDA approval decisions in Q3 2026

Swetha Kota Jul 01, 2026 pp. 506-506 10.1038/d41573-026-00103-8

Antiviral peptide nabs FDA approval for hepatitis delta virus infection

Asher Mullard Jul 01, 2026 pp. 502-502 10.1038/d41573-026-00101-w

First CD123-targeted ADC secures FDA approval for rare blood cancer

Asher Mullard Jul 01, 2026 pp. 501-501 10.1038/d41573-026-00100-x

Advancing ferroptosis-targeted therapies

M. Teresa Villanueva Jul 01, 2026 pp. 513-513 10.1038/d41573-026-00098-2

Analysis of a decade of post-authorisation studies for medicines approved by the EMA

Caroline Voltz-Girolt, Guillem Wetherell Mateu, Carla Torre et al. Jul 01, 2026 pp. 504-505 10.1038/d41573-026-00082-w

Implantable hydrogel encapsulates ‘living therapeutics’

Katie Kingwell Jul 01, 2026 pp. 514-514 10.1038/d41573-026-00096-4

Reply to ‘Stimulating medicines repurposing in the EU: a pilot project’

Pan Pantziarka, Patricia Vandamme, Alicia Soler et al. Jul 01, 2026 pp. 576-576 10.1038/s41573-026-01473-9

ASO sustains microglial neural repair activity

Alex Eccleston Jul 01, 2026 pp. 511-511 10.1038/d41573-026-00095-5

Therapeutic and prophylactic strategies for Ebola caused by Bundibugyo virus

Jean B. Nachega, Jean-Jacques Muyembe-Tamfum, Alimuddin Zumla Jul 01, 2026 pp. 495-496 10.1038/d41573-026-00094-6

Understanding Ras inhibitor resistance

Sarah Crunkhorn Jul 01, 2026 pp. 515-515 10.1038/d41573-026-00091-9

Informing HIV vaccine design

Sarah Crunkhorn Jul 01, 2026 pp. 515-515 10.1038/d41573-026-00093-7

Inhibiting lactate transport reduces lung fibrosis

Sarah Crunkhorn Jul 01, 2026 pp. 515-515 10.1038/d41573-026-00090-w

Inhibiting Nipah virus

Sarah Crunkhorn Jul 01, 2026 pp. 515-515 10.1038/d41573-026-00092-8

Incretin-based multi-agonist reverses obesity and diabetes

Sarah Crunkhorn Jul 01, 2026 pp. 512-512 10.1038/d41573-026-00087-5

FDA approves first-in-class hypertension drug

Asher Mullard Jul 01, 2026 pp. 501-501 10.1038/d41573-026-00085-7

The landscape for therapeutic cancer vaccines

Congzhou Chen, Xue Wang, Wei Wei et al. Jul 01, 2026 pp. 509-510 10.1038/d41573-026-00063-z

The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond

Erik S. Knudsen, Agnieszka K. Witkiewicz, Sheheryar Kabraji Jul 01, 2026 pp. 516-533 10.1038/s41573-026-01431-5

Target identification and assessment in the era of AI

Frank W. Pun, Dmitriy Podolskiy, Evgeny Izumchenko et al. Jul 01, 2026 pp. 534-552 10.1038/s41573-026-01412-8

The expanding role of formulations to enable oral delivery of poorly water-soluble drugs

Keisuke Ueda, Christopher J. H. Porter, Aaron Goodwin et al. Jul 01, 2026 pp. 553-575 10.1038/s41573-026-01407-5